Last reviewed · How we verify

Methotrexate + Infliximab — Competitive Intelligence Brief

Methotrexate + Infliximab (Methotrexate + Infliximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: antimetabolite + TNF-α inhibitor. Area: Immunology / Rheumatology.

marketed Combination therapy: antimetabolite + TNF-α inhibitor Dihydrofolate reductase (methotrexate); TNF-α (infliximab) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate + Infliximab (Methotrexate + Infliximab) — Université Catholique de Louvain. Methotrexate suppresses immune cell proliferation while infliximab blocks tumor necrosis factor-alpha, together reducing inflammatory and autoimmune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Methotrexate + Infliximab TARGET Methotrexate + Infliximab Université Catholique de Louvain marketed Combination therapy: antimetabolite + TNF-α inhibitor Dihydrofolate reductase (methotrexate); TNF-α (infliximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: antimetabolite + TNF-α inhibitor class)

  1. Université Catholique de Louvain · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate + Infliximab — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-infliximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: